Tatva Chintan Pharma Chem Limited
NSE: TATVA · Specialty Chemicals
Snapshot
Unlock Tatva Chintan Pharma Chem Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Tatva Chintan Pharma Chem Limited is a specialty chemicals manufacturer specialising in structure directing agents, phase transfer catalysts, and electrolyte salts. The company serves a diverse range of industries including automotive, pharmaceutical, and agro-chemicals, with a global footprint spanning approximately 25 countries.
Business Model
The company generates revenue through the manufacturing and sale of complex specialty chemicals, intermediates, and catalysts, alongside the trading of chemical products. It leverages its expertise in quaternary ammonium compounds to supply critical components to the automotive, petroleum, and personal care sectors.
Growth Outlook
Growth is driven by the increasing demand for specialty chemicals in the electric vehicle battery sector and the expansion of its portfolio in pharmaceutical intermediates. The company continues to focus on international market penetration and the development of high-value chemical solutions.
Key Risks
- Raw Material Price Volatility. Fluctuations in the cost of key chemical feedstocks can significantly impact operating margins.
- Regulatory and Environmental Compliance. Stringent environmental regulations in the chemical manufacturing sector may necessitate high capital expenditure for compliance.
- Geopolitical and Export Risks. As an exporter to over 25 countries, the company is susceptible to international trade barriers and currency exchange rate volatility.
- Customer Concentration. Dependence on specific industries like automotive and pharmaceuticals exposes the company to cyclical downturns in those sectors.
Start your research today
Unlock AI insights, financials, peers and live data on Tatva Chintan Pharma Chem Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹650 Cr
TTM · consolidated
NET PROFIT
₹63 Cr
TTM · consolidated
EPS
₹26.90
TTM · consolidated
RETURN ON EQUITY
8.0%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
11.5%
TTM · consolidated
P/E
61.8×
Q2 FY27 · consolidated
EV/EBITDA
30.5x
Q2 FY27 · consolidated
EBITDA MARGIN
20.4%
TTM · consolidated
NET PROFIT MARGIN
9.9%
Q2 FY27 · consolidated
DEBT TO EQUITY
0.2x
Q2 FY27 · consolidated
Peers · Specialty Chemicals
| Company | Mkt Cap | P/E (TTM) | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Tatva Chintan Pharma Chem LimitedTATVA | ₹3,887 Cr | 61.8× | 30.53 | 49.7% | 20.4% | 8.0% | 11.5% | +16.8% |
Foseco India LimitedFOSECOIND | ₹4,424 Cr | 53.3× | 32.76 | 10.3% | 20.6% | 11.0% | 15.3% | +2.8% |
Laxmi Organic Industries LimitedLXCHEM | ₹4,324 Cr | 34.3× | 17.91 | 5.5% | 8.6% | 6.5% | 8.3% | -20.6% |
Epigral LimitedEPIGRAL | ₹4,105 Cr | 15.1× | 7.85 | 4.8% | 22.6% | 13.1% | 15.5% | -43.7% |
Yasho IndustriesYASHO | ₹3,930 Cr | 45.4× | 20.13 | 54.6% | 20.5% | 18.4% | 19.6% | +105.0% |
Vishnu Chemicals LimitedVISHNU | ₹3,439 Cr | 22.5× | 13.76 | 14.1% | 17.3% | 14.2% | 17.1% | -1.0% |
As of Q2 FY27
Financials
Tatva Chintan Pharma Chem Limited
NSE: TATVA · Specialty Chemicals
Snapshot
Unlock Tatva Chintan Pharma Chem Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Tatva Chintan Pharma Chem Limited is a specialty chemicals manufacturer specialising in structure directing agents, phase transfer catalysts, and electrolyte salts. The company serves a diverse range of industries including automotive, pharmaceutical, and agro-chemicals, with a global footprint spanning approximately 25 countries.
Business Model
The company generates revenue through the manufacturing and sale of complex specialty chemicals, intermediates, and catalysts, alongside the trading of chemical products. It leverages its expertise in quaternary ammonium compounds to supply critical components to the automotive, petroleum, and personal care sectors.
Growth Outlook
Growth is driven by the increasing demand for specialty chemicals in the electric vehicle battery sector and the expansion of its portfolio in pharmaceutical intermediates. The company continues to focus on international market penetration and the development of high-value chemical solutions.
Key Risks
- Raw Material Price Volatility. Fluctuations in the cost of key chemical feedstocks can significantly impact operating margins.
- Regulatory and Environmental Compliance. Stringent environmental regulations in the chemical manufacturing sector may necessitate high capital expenditure for compliance.
- Geopolitical and Export Risks. As an exporter to over 25 countries, the company is susceptible to international trade barriers and currency exchange rate volatility.
- Customer Concentration. Dependence on specific industries like automotive and pharmaceuticals exposes the company to cyclical downturns in those sectors.
Start your research today
Unlock AI insights, financials, peers and live data on Tatva Chintan Pharma Chem Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹650 Cr
TTM · consolidated
NET PROFIT
₹63 Cr
TTM · consolidated
EPS
₹26.90
TTM · consolidated
RETURN ON EQUITY
8.0%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
11.5%
TTM · consolidated
P/E
61.8x
Q2 FY27 · consolidated
EV/EBITDA
30.5x
Q2 FY27 · consolidated
EBITDA MARGIN
20.4%
TTM · consolidated
NET PROFIT MARGIN
9.9%
Q2 FY27 · consolidated
DEBT TO EQUITY
0.2x
Q2 FY27 · consolidated
Peers · Specialty Chemicals
As of Q2 FY27